Condition

Muscle Wasting

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common interventions8

Lead sponsors shown3

Clinical trials

4 shown

Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.NCT07411378 · 2026-07-01

NOT_YET_RECRUITING

Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2NCT01624792 · 2011-10-25

COMPLETED

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumNCT01355497 · 2011-07-01

COMPLETED

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)NCT01355484 · 2011-07-01

COMPLETED

Common interventions

GTx-024DRUG2 placeboDRUG2 BIO101DRUG1 Fish oilDIETARY_SUPPLEMENT1 Fish oil and placeboDIETARY_SUPPLEMENT1 Olive oilDIETARY_SUPPLEMENT1 PlaceboOTHER1 SemaglutideDRUG1

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

placebo2 semaglutide1

Leading sponsors

GTx 2 Biophytis 1 Texas A&M University 1

Trial status mix

COMPLETED3

NOT_YET_RECRUITING1

Phase mix

PHASE32

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.